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Background: The aim of the RECCORD registry was to gather real-world UK data on the use of targeted therapies in
renal cell carcinoma (RCC) and assess clinical outcomes. Here, demographic and outcome data are presented with the
treatment patterns and demographic profile of patients on the registry.
Patients and methods: Patients were retrospectively identified at seven UK hospitals with large cancer centres in
England (5), Scotland (1) and Wales (1). Anonymised data were collected through an online registry covering demograph-
ics, treatments and outcomes. Five hundred and fourteen UK adult patients with metastatic RCC were included in the
study for analysis. Patients were included if they were treated for metastatic RCC at one of the seven centres, and started
systemic anti-cancer treatment from March 2009 to November 2012 inclusive. In addition to demographic factors, the
principal outcome measures were overall survival (OS), time to disease progression and toxicity.
Results: The majority of first-line treatment was with sunitinib; first-line use of pazopanib increased as the study
progressed. 15.8% of patients received second-line treatment, half of whom were prescribed everolimus. Median OS
(from initiation of first-line treatment) was 23.9 months (95% confidence interval [CI] 18.6–29.1 months), similar to that
reported for clinical trials of targeted RCC therapies [Ljungberg B, Campbell SC, Choi HY et al. The epidemiology of renal
cell carcinoma. Eur Urol 2011; 60: 615–621; Abe H, Kamai T. Recent advances in the treatment of metastatic renal cell
carcinoma. Int J Urol 2013; 20: 944–955; Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated
results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;
27: 3584–3590]. OS was significantly longer for those who received second-line treatment after disease progression
(33.0 months; 95% CI 30.8–35.2 months) than those who did not (20.9 months; 95% CI 16.4–25.3 months; P = 0.008).
Conclusions: RECCORD is a large ‘real-world’ database assessing metastatic RCC treatment patterns and outcomes.
Treatment patterns changed over time as targeted therapies were approved and became widely available; survival data in
RECCORD are consistent with those reported for systemic treatments in clinical trials. Kaplan–Meier analysis of results
demonstrated that receiving second-line therapy was a major prognostic factor for longer OS.
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introduction
Renal cell carcinoma (RCC) is a malignancy that accounts for
over 90% of kidney cancers [1]. Clear cell RCC is the most
common (70%–85%) [2]. Approximately 30% of all RCC patients
have metastatic disease at presentation, and until recently, treat-
ment options were limited as these cancers are relatively resistant
to cytotoxic chemotherapy [2]. However, the introduction of tar-
geted therapy has significantly improved the prognosis and treat-
ment outcome for these patients [3–5]. These therapies target the
vascular endothelial growth factor (VEGF) pathway and the
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mammalian target of rapamycin (mTOR) pathway, both of which
are related to the pathogenesis of clear cell metastatic RCC [6].
Despite this progress, there are still a number of treatment chal-
lenges, including identifying and optimising the most appropriate
sequences or combinations of agents and managing associated
side-effects. Health-related quality of life has also become an im-
portant medical outcome among this patient population, particu-
larly since there is evidence that tumour response and delay in
disease progression can affect it [7, 8].
Clinical guidelines for the treatment of metastatic RCC reflect
clinical trial evidence for targeted therapy [9–11]. Trial popula-
tions may not represent real-life patient populations and have
better outcomes than patients ineligible for studies [12, 13].
Optimisation of disease management must therefore be based
on clinical trials and real-world experience [14]. Worldwide,
registries provide insights into treatment patterns and outcomes
for patients with RCC in the real world [15–17]. Their results
suggest that survival has improved in the era of targeted therap-
ies compared with the era of cytokine therapy [15, 16]. While
the sunitinib expanded access programme included patients
from the UK [18], real-life data for RCC management in UK
clinical practice are limited. These data could provide important
information on disease progression, as well as facilitating opti-
misation of treatment.
The aim of the Renal Cell Carcinoma Outcomes Research
Dataset (RECCORD) registry was to collect real-world demo-
graphic, treatment, histological and outcome data from RCC
patients in the UK. Here, we report on the demographics of
RECCORD, the current use of systemic therapy and the clinical
outcome associated with different therapeutic approaches.
methods
patients
A retrospective, non-interventional study was conducted using data from the
medical records of eligible patients. To be eligible, patients were required to
meet the following inclusion criteria: (i) have histologically confirmed clear
cell locally advanced or metastatic RCC, (ii) started systemic therapy [tyro-
sine kinase inhibitors, mTOR inhibitors, anti-VEGF agents, and cytokine
therapy, including interferon-alpha or interleukin-2 (IL-2), or other]
between 1 March 2009 and 31 October 2012 and (iii) aged ≥18 years at the
time of diagnosis of RCC.
Patients treated as part of clinical research trials were included.
data source
RECCORD is a web-based registry system that comprises data from seven
UK centres specialising in RCC (Bristol, Birmingham, Manchester, London,
Leeds, Swansea and Glasgow). Medical records of eligible patients were
retrospectively abstracted and the data held on the centre’s local database,
then transferred to a central server where they were combined and analysed.
Data collection was from March 2009 to October 2012. Patients were identi-
fied by a unique RECCORD sequence number, but no other patient identi-
fiers were collected to ensure anonymity. The registry was regulated by
the RECCORD Steering Committee, comprised of recognised experts in the
management of RCC. RECCORD was conducted according to the Declaration
of Helsinki. The study protocol was approved by the NHS Research Ethics
Committee, local ethics committees and the principal investigators at each
centre.
outcome variables
The outcomes of interest included survival, disease progression, treatment
patterns (systemic therapies used and dose changes or discontinuation of
therapy) and treatment toxicity. Disease progression was assessed using radi-
ology, symptomatology, clinical investigation and therapy change as markers,
and included death. Patterns of switching from first- to second- and third-line
treatment were also examined. Switch to second-line treatment was defined as
a switch due to disease progression only; changes in treatment due to reasons
of toxicity were considered as an extension of first-line treatment. Some
patient records did not include data for all parameters; available data from
these patients were used where appropriate.
statistical analysis
Descriptive statistics were used to describe baseline characteristics, treatment
patterns and adverse events. Changes in treatment patterns were considered
for three 12-month cohorts (March 2009–February 2010; March 2010–
February 2011 and March 2011–February 2012). Overall survival (OS),
disease progression and treatment toxicity data were analysed from the onset
of first systemic therapy using Kaplan–Meier survival curves. Relationships
between outcomes, demographic factors and treatment patterns were assessed
using Kaplan–Meier analyses and log-rank comparisons. All statistical ana-
lyses were carried out using SPSS for Windows 15.0 (SPSS, Inc., Chicago, IL,
USA).
results
patient characteristics
In total, 514 patients were eligible for inclusion and retrospect-
ively analysed (Table 1). All patients had metastatic disease, and
56.3% had stage IV disease at diagnosis; however, the sites of
metastases were not routinely captured within RECCORD.
Mean age at diagnosis was 61.6 years [standard deviation (SD):
10.9], and 66% of patients were male. Patients were enrolled
from England (66.7%), Wales (10.3%), and Scotland (23.0%).
56.8% of patients enrolled in Scotland joined the study in 2009
(reflecting a national delay in access to treatment).
Table 1. Baseline characteristics of patients in RECCORD (n = 514)
Male, n (%)a 341 (66.3)
Mean age at diagnosis; years (SD)b 61.6 (10.9)
Mean time from diagnosis to
enrolment; years (SD)c
2.1 (3.6)
Patients with nephrectomy, n (%) 257 (50.0)
Total nephrectomy, n (%) 164 (63.8% of all nephrectomies)
With curative intent, n (%) 87 (53.0%)
Without curative intent, n (%) 37 (22.6%)
Unknown intent, n (%) 40 (24.4%)
Partial nephrectomy, n (%) 11 (4.3% of all nephrectomies)
With curative intent, n (%) 5 (45.5%)
Without curative intent, n (%) 2 (18.2%)
Unknown intent, n (%) 4 (36.4%)
Nephrectomy with unknown
extent, n (%)
82 (31.9% of all nephrectomies)
aThe gender of two patients was not recorded.
bThirty patients excluded due to missing data.
cTwenty-four patients excluded due to missing data.
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first-line therapies. The first-line therapies for the RECCORD
population are detailed in Table 2. Sunitinib was the first-line
treatment in 78.6% of cases, followed by pazopanib (11.7%) and
everolimus (6.4%); 35 patients (6.8%) changed first-line therapy
due to toxicity. A decline in the number of different first-line
treatments was observed; seven different treatments were used
in the 2009–2010 cohort, compared with four in 2011–2012
(sunitinib, pazopanib, everolimus and sorafenib). First-line
treatment with pazopanib increased from 0.9% in 2009–2010 to
27.1% in 2011–2012, following European marketing approval
[19]. Everolimus was used as part of a first-line clinical trial in
32 patients (6.2%).
second-line and third-line therapies. Second-line treatment was
received by 15.8% of patients, with a substantial regional variation
in its use (Scotland: 8.5%; Wales: 7.5%; England: 19.5%).
Everolimus (53.1%), sunitinib (14.8%) and pazopanib (9.9%) were
the most commonly used second-line treatments (Table 2).
The use of second-line treatment increased between the first
(2009–2010) and second (2010–2011) cohorts (17.3% and
20.4%, respectively); a smaller proportion of the third cohort
(2011–2012) switched to second-line treatment (13.9%) due to
the shorter study period. The mean length of time before
second-line switch decreased from 17.4 ± 11.8 months (2009–
2010 cohort) to 12.3 ± 7.1 months (2010–2011 cohort). Time to
second-line switch was lower again in the 2011–2012 cohort
(6.3 ± 3.7 months), reflecting the shorter follow-up for these
patients.
Similar to first-line treatment, more different treatments were
used second-line in 2009–2010 (8) than in 2011–2012 (5).
Sixteen (3.1%) of the RECCORD cohort received third-line
treatment (Table 2). Everolimus was the dominant third-line
treatment of patients enrolled in 2009–2010 (seven of nine
patients), and this decreased over time while the use of axitinib
increased. Patients who received third-line treatment were all
enrolled in England.
At the end of the study, 95 of 514 (18.5%) patients were still
on first-line treatment; 10 had switched first-line treatment due
to toxicity. Twenty-one of 81 (25.9%) patients were still on
second-line treatment.
overall survival
Almost half of patients (49.8%) died during the study period.
Median OS from the start of treatment was 23.9 months
(Figure 1A).
The relationship between OS and individual demographic
factors and treatment patterns was assessed. A number of factors
were associated with increased survival (Table 3). Median OS of
patients who received second-line treatment (33.0 months) was
significantly longer (P = 0.008; Figure 1B) than that of patients
who only received first-line treatment (20.9 months). A similar
Table 2. Systemic treatment patterns among patients with advanced
RCC in RECCORD
Agent First-line
(n = 514)
n (%)
Second-line
(n = 81)
n (%)
Third-line
(n = 16)
n (%)
Sunitinib 404 (78.6) 12 (14.8) –
Pazopanib 60 (11.7) 8 (9.9) –
Everolimus 33 (6.4) 43 (53.1) 8 (50.0)
Sorafenib 6 (1.2) 3 (3.7) 1 (6.3)
Temsirolimus 4 (0.8) 1 (1.2) –
Axitinib – 4 (4.9) 5 (31.3)
IL-2 3 (0.6) 2 (2.5) –
Interferon-alpha 2 (0.4) – 1 (6.3)
Other 2 (0.4) 8 (9.9) 1 (5.9)
Thirty-five patients also switched to a different first-line treatment due
to toxicity (see text).
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Figure 1. Kaplan–Meier survival plots of mortality in RECCORD. Kaplan–Meier analysis of: (A) overall survival of the RECCORD cohort; (B) survival with
and without second-line treatment; (C) survival with and without third-line treatment. Crosses represent censored cases. Kaplan–Meier estimates of median
survival with 95% confidence intervals (CI) are presented below.
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pattern was seen when considering the switch to third-line treat-
ment (Figure 1C), although it did not attain statistical signifi-
cance, most likely due to the limited number of patients in this
group.
The length of time between diagnosis and systemic treatment
was significantly associated with OS (P < 0.001); OS from the
start of systemic treatment was lower for patients treated within
100 days of diagnosis than for those who did not receive treat-
ment until 600 days or more after diagnosis.
There was also a significant association between toxicity-
induced dose decreases and OS (P = 0.002). The median survival
time for patients with first-line treatment dose decreases was
30.6 months; for other patients, it was 19.8 months.
disease progression
At the time of analysis, disease progression had been experi-
enced by the majority (66.1%) of patients on first-line therapy
(median duration of follow-up: 13.1 months, 95% CI 12.0–14.1
months). Median time to disease progression was 8.8 months
(95% CI 7.7–9.9 months; Figure 2). There was a significant asso-
ciation between the time from RCC diagnosis to first-line treat-
ment and disease progression (X2(5) = 13.521, P = 0.019).
Estimated time to progression was shortest for patients who had
started first-line treatment within 100 days of diagnosis (16.8
months [95% CI 14.1–19.5 months]).
treatment toxicity
Dose decreases and discontinuations of systemic therapy due to
toxicity are summarised in Table 4. In total, 30.5% patients had
their first-line treatment dose decreased due to toxicity, and
Table 3. Demographic factors and treatment patterns associated with survival of RCC patients
Variable (n) Kaplan–Meier estimate of median
survival time; months (95% CI)
Second-line treatment (X2(1) = 7.031; P = 0.008) No second-line (431) 20.9 (16.4–25.3)
Received second-line (81) 33.0 (30.8–35.2)
Third-line treatment
(X2(1) = 2.619; P = 0.106)
No third-line (496) 23.4 (19.3–27.6)
Received third-line (16) 33.9 (25.2–42.6)
Time from diagnosis to systemic treatment split by band in daysa
(X2(5) = 28.713; P < 0.001)
0–100 (185) 13.6 (9.7–17.4)
100–200 (n = 59) 19.3 (7.1–31.6)
200–300 (n = 29) 32.2 (–)
300–400 (n = 29) 23.4 (8.7–38.2)
400–600 (n = 33) 25.4 (12.9–37.9)
>600 (155) 36.9 (31.9–41.9)
Time from diagnosis to systemic treatment using a 365-day splita
(X2(1) = 19.174; P < 0.001)
0–365 (290) 16.5 (10.8–22.2)
>365 (200) 33.6 (27.5–39.7)
Time to progression split by band in days (X2(1) = 138.828; P < 0.001) 0–100 (95) 5 (2.9–7.1)
100–200 (n = 72) 8.5 (7.1–9.9)
200–300 (n = 55) 16.8 (11.1–22.4)
300–400 (n = 44) 23.4 (11–35.7)
>400 (75) 47.3 (–)b
Genderc
(X2(1) = 2.774, P = 0.096)
Male (339) 28.8 (22.1–35.4)
Female (171) 21.9 (16.6–27.1)
Dose decreases
(X2(1) = 9.434; P = 0.002)
No dose decrease (355) 19.8 (14.7–24.9)
Received decrease (157) 30.6 (25–36.3)
aDate of diagnosis was not recorded for 22 patients.
b95% CI was not calculable.
cGender of two patients was not recorded. All survival estimates are from the start of systemic treatment in RECCORD. Time to systemic treatment is from
diagnosis, and time to progression is from the start of systemic treatment. Two records were excluded from analysis due to irregularities with recorded date
of death.
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Figure 2. Kaplan–Meier survival plot of time to disease progression on
first-line treatment.
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17.8% of these had a further dose decrease due to toxicity. First-
line therapy was switched for 35 patients (6.8%) due to toxicity
(32 to pazopanib and 3 to sorafenib). The median time to first
reported toxic event on first-line therapy was 3.1 months (95%
CI 2.0–4.2 months). The median time to discontinuation of a
first-line drug was 4.0 months (95% CI 0.2–5.8 months).
Kaplan–Meier analyses did not identify any factors that had a
statistically significant association with toxicity.
discussion
RECCORD is the first UK-specific registry to provide information
on real-world treatment patterns and outcomes of RCC patients
treated with a range of systemic therapies. We found systemic
RCC treatments to be used in accordance with clinical guidelines;
fewer treatment options were used as the study progressed.
Additionally, patients receiving second-line treatment survived
longer than those who did not. The treatment of advanced RCC
has changed in the past 5 years with new treatment options sig-
nificantly improving outcomes. The licensing of targeted therap-
ies before and during RECCORD are reflected in the changing
patterns of treatment [20–22]. Sunitinib and pazopanib were the
predominant first-line treatments, with the shift from sunitinib to
pazopanib driven by the expectation of improved patient quality
of life with the latter [23, 24].
15.8% of RECCORD patients received second-line therapy,
with over half treated with everolimus. This low proportion re-
ceiving second-line treatment may reflect the limited access to
these therapies in the UK; there was a pattern of increased use of
second-line therapy over time but with regional variability in
access. In England, money to increase access to treatments not
routinely funded by the NHS is available through a cancer drugs
fund [25]. There is no cancer drug fund in Wales or Scotland,
leading to markedly lower rates of second-line treatment.
Median OS from the start of systemic treatment in RECCORD
was estimated at 22.3 months. This is consistent with clinical
trials of systemic therapies including pazopanib (22.9 months)
[4], sunitinib (26.4 months) [3] and bevacizumab (23.3 months)
[26]. Several factors assessed in RECCORD were found to be
associated with OS. Most notably, the OS of patients who
switched to second-line therapy was significantly longer than
those who did not switch. This may be due to selection bias
(good prognosis patients are more likely to receive further
therapy), an artefact of the relatively short follow-up period in
the study, or because post first-line therapy is causing prolonga-
tion of survival. Clinical trials have shown that second-line ther-
apies, e.g. everolimus and axitinib, improve quality of life and
extend progression-free survival, but have failed to conclude
prolongation of survival [27, 28]. Clearly, there is a need to
improve general access to these beneficial agents and equalise
such access across the UK.
A length of time between diagnosis and systemic treatment of
<365 days is established as a marker for poor prognosis and sur-
vival [29, 30]. In this study, there was a significantly longer OS
for patients with longer than 365 days between diagnosis and
treatment than those with a shorter interval (P > 0.001).
However, further analysis showed that it was the extreme inter-
vals (<100 days or over 600 days) that underlie this association
with survival. Between 100 and 600 days, there was a gradual in-
crease in survival associated with increasing delay from diagno-
sis to treatment. This analysis suggests the potential for
improved accuracy of prognosis thorough more precise record-
ing of the time from diagnosis to treatment.
There was also an apparent association between first-line
treatment toxicity-induced dose decreases with increased sur-
vival. The widespread use and investigation of sunitinib has led
to reports linking increased survival to toxicity-induced dose
reductions [31] or to incidence of side-effects, such as hyperten-
sion [32] and hypothyroidism [33]. As these links are not com-
monly investigated in trials, no such reports have been found for
other treatments utilised within RECCORD. Many factors may
contribute to this link, such as clinicians being more at ease with
dose reductions in patients performing well, that these patients
received a higher exposure to the drug (causing toxicity) result-
ing in greater efficacy, or because patients with poor prognoses
are not on therapy long enough to experience dose reductions.
Our study had several strengths and provides important
insights into treatment patterns and outcomes of patients with
advanced RCC in a ‘real-life’ setting. The data provided by the
registry will enable clinicians to better understand the utilisation
and outcomes associated with systemic treatment. RECCORD is
a secure, web-based registry system that allows data to be
uploaded from the local clinical centres to a central database.
Further analysis of outcomes and prognostic factors not
reported in this initial study will allow greater understanding of
the effect of disease stage and laboratory markers of disease ac-
tivity on clinical outcomes in the UK. Limitations to our study
included the risk of bias inherent in retrospective studies, the
Table 4. Dose decreases and discontinuations of systemic therapy due to toxicity
First-line (n = 514)
n (%)
Second-line (n = 81)
n (%)
Third-line (n = 16)
n (%)
Patients decreasing dose due to toxicity 157 (30.5) 9 (11.1) 2 (7.4)
Patients with >1 toxicity-induced dose decrease 28 (17.8)a 0 (0.0) 0 (0.0)
Patients decreasing dose due to ‘other’ reason 16 (3.1) 0 (0.0) 0 (0.0)
Patients discontinuing due to toxicity 97 (18.9)b 12 (14.8) 2 (12.5)
Patients discontinuing due to toxicity after toxicity-induced dose reduction 27 (17.1)a 0 (0.0) 0 (0.0)
Absolute patient numbers are given with percentage values in brackets.
aAs a percentage of patients who already experienced one dose decrease.
bIncludes n = 35 patients who changed to a different first-line treatment due to toxicity.
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relatively modest numbers enrolled from Wales and Scotland,
and follow-up periods that varied substantially. Additionally,
databases are prone to incomplete or late entries of clinical data,
or data input errors. A small number of the RECCORD patients
were taking part in clinical trials (32 patients on first-line evero-
limus), and so their inclusion would only have had a small
overall effect.
In conclusion, registries are becoming important tools to help
make more informed treatment decisions since data are repre-
sentative of a real-world setting. Our results provide valuable
information on the outcomes and systemic treatment of patients
with metastatic RCC, which remains a major therapeutic chal-
lenge. This study shows that as RECCORD progressed, there
was a simplification of clinical decision-making as systemic
treatments became routinely available. Additionally, there was a
significant association between increased survival and treatment
beyond first-line therapy. This is important because access to
second-line treatments is not equitable across the UK, risking
differences in the quality of RCC care and outcomes across the
UK arising.
These data are useful for devising future sequencing studies in
advanced RCC, as well as adding valuable ‘real-life’ evidence to
previous clinical trial data. Data from RECCORD therefore have
a central role in improving care and outcomes for people with
RCC.
acknowledgements
The authors thank Jennifer Laskey (Beatson West of Scotland
Cancer Centre, Glasgow), Chloe Rodger (University Hospitals
Bristol) and Laura Crack (Queen Elizabeth Hospital,
Birmingham) for their contributions to the study.
funding
This work was supported by Novartis Pharmaceuticals UK Ltd
(no grant number). The sponsors of the study had no role in
study design, data collection, data analysis, data interpretation
or writing of the report.
disclosure
All authors have support from Novartis for the submitted work.
Outside the submitted work, AB declares relationships with
Novartis and Pfizer, EP declares relationships with Pfizer and
GSK, JB declares relationships with Novartis and Amgen, LP
declares relationships with Novartis, Pfizer and GSK and RJ
declares relationships with GSK and Roche. RH declares rela-
tionships with Pfizer, GSK and Novartis.
references
1. Ljungberg B, Campbell SC, Choi HY et al. The epidemiology of renal cell
carcinoma. Eur Urol 2011; 60: 615–621.
2. Abe H, Kamai T. Recent advances in the treatment of metastatic renal cell
carcinoma. Int J Urol 2013; 20: 944–955.
3. Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for
sunitinib compared with interferon alfa in patients with metastatic renal cell
carcinoma. J Clin Oncol 2009; 27: 3584–3590.
4. Sternberg CN, Hawkins RE, Wagstaff J et al. A randomised, double-blind phase III
study of pazopanib in patients with advanced and/or metastatic renal cell
carcinoma: final overall survival results and safety update. Eur J Cancer 2013; 49
(6): 1287–1296.
5. Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic
renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;
116: 4256–4265.
6. Mulders P. Vascular endothelial growth factor and mTOR pathways in renal cell
carcinoma: differences and synergies of two targeted mechanisms. BJU Int 2009;
104: 1585–1589.
7. Cella D. Beyond traditional outcomes: improving quality of life in patients with renal
cell carcinoma. Oncologist 2011; 16(Suppl 2): 23–31.
8. Lambea J, Hinojo C, Lainez N et al. Quality of life and supportive care for patients
with metastatic renal cell carcinoma. Cancer Metastasis Rev 2012; 31(Suppl 1):
S33–S39.
9. Escudier B, Eisen T, Porta C et al. ESMO Guidelines Working Group. Renal cell
carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-
up. Ann Oncol 2012; 23(Suppl 7): vii65–vii71.
10. Ljungberg B, Bensalah K, Bex A et al. EAU guidelines on renal cell carcinoma, 2013.
http://uroweb.org/wp-content/uploads/08-Renal-Cell-Carcinoma_LR.pdf (August 2015,
date last accessed).
11. Nathan P, Wagstaff J, Porfiri E et al. UK guidelines for the systemic treatment of
renal cell carcinoma. Br J Hosp Med (Lond) 2009; 70: 284–286.
12. Molina AM, Motzer RJ. Clinical practice guidelines for the treatment of metastatic
renal cell carcinoma: today and tomorrow. Oncologist. 2011; 16(Suppl 2): 45–50.
13. Heng DY, Choueiri TK, Rini BI et al. Outcomes of patients with metastatic renal cell
carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol 2014; 25
(1): 149–154.
14. Schmidinger M, Larkin J, Porta C. Evidence and experience for the management
of metastatic renal cell carcinoma. EJC Suppl 2013; 11: 1–8.
15. Shek D, Tomlinson B, Brown M et al. Epidemiologic trends in renal cell carcinoma
in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients. Clin
Genitourin Cancer 2012; 10: 93–98.
16. Vaishampayan U, Vankayala H, Vigneau FD et al. The effect of targeted therapy on
overall survival in advanced renal cancer: a study of the National Surveillance
Epidemiology and End Results Registry Database. Clin Genitourin Cancer 2014; 12
(2): 124–129.
17. Ta AD, Bolton DM, Dimech MK et al. Contemporary management of renal cell
carcinoma (RCC) in Victoria: implications for longer term outcomes and costs. BJU
Int 2013; 112(Suppl 2): 36–43.
18. Gore ME, Hariharan S, Porta C et al. Sunitinib in metastatic renal cell carcinoma
patients with brain metastases. Cancer 2011; 117(3): 501–509.
19. European Medicines Agency. Votrient ( pazopanib) EPAR summary for the public.
2013.
20. Afinitor Summary of Product Characteristics. Novartis Ltd. 2009.
21. National Institute for Health and Care Excellence. Sunitinib for the first-line
treatment of advanced and/or metastatic renal cell carcinoma, 2009.
22. National Institute for Health and Care Excellence. Pazopanib for the first-line
treatment of advanced renal cell carcinoma, 2011.
23. Motzer RJ, Hutson TE, Cella D et al. Pazopanib versus sunitinib in metastatic renal-
cell carcinoma. N Engl J Med 2013; 369: 722–731.
24. Escudier B, Porta C, Bono P et al. Randomized, controlled, double-blind, cross-
over trial assessing treatment preference for pazopanib versus sunitinib in patients
with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol 2014; 32(14):
1412–1418.
25. NHS England. The Cancer Drugs Fund. 2014. http://www.england.nhs.uk/
ourwork/pe/cdf/ (August 2015, date last accessed).
26. Escudier B, Bellmunt J, Négrier S et al. Phase III trial of bevacizumab plus
interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final
analysis of overall survival. J Clin Oncol 2010; 28(13): 2144–2150.
27. Rini BI, Escudier B, Tomczak P et al. Comparative effectiveness of axitinib versus
sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Lancet 2011; 378: 1931–1939.
28. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal
cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
Lancet 2008; 372: 449–456.
 | Wagstaff et al. Volume 27 | No. 1 | January 2016
original articles Annals of Oncology
29. Heng DY, Xie W, Regan MM et al. External validation and comparison with
other models of the International Metastatic Renal-Cell Carcinoma Database
Consortium prognostic model: a population-based study. Lancet Oncol 2013; 14(2):
141–148.
30. Bukowski RM. Prognostic factors for survival in metastatic renal cell carcinoma.
Cancer 2009; 115(Suppl 10): 2273–2281.
31. Livne-Segev D, Gottfried M, Maimon N et al. Experience with sunitinib
treatment for metastatic renal cell carcinoma in a large cohort of Israeli
patients: outcome and associated factors. Isr Med Assoc J 2014; 16:
347–351.
32. Rini BI, Cohen DP, Lu DR et al. Hypertension as a biomarker of efficacy in patients
with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst
2011; 103: 763–773.
33. Baldazzi V, Tassi R, Lapini A et al. The impact of sunitinib-induced hypothyroidism
on progression-free survival of metastatic renal cancer patients: a prospective
single-center study. Urol Oncol 2012; 30(5): 704–710.
Annals of Oncology 27: 165–172, 2016
doi:10.1093/annonc/mdv486
Published online 20 October 2015
Comprehensive serum cytokine analysis identifies
IL-1RA and soluble IL-2Rα as predictors
of event-free survival in T-cell lymphoma
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Background: T-cell malignancies are heterogeneous in their clinical presentation and pathology, and have a poor prog-
nosis. New biomarkers are needed to predict prognosis and to provide insights into signal pathways used by these cells.
The goal of this study was to evaluate pretreatment serum cytokines in patients with newly diagnosed T-cell neoplasms
and correlate with clinical outcome.
Patients and methods: We evaluated 30 cytokines in pretreatment serum from 68 untreated patients and 14 normal
controls. Significantly elevated cytokines were correlated with patterns of abnormalities, event-free survival (EFS) and
overall survival (OS).
Results: Our data demonstrated significantly elevated levels (versus controls) of seven cytokines—epidermal growth
factor (EGF), IL-6, IL-12, interferon gamma-induced protein (IP)-10, soluble interleukin (sIL)-2Rα, monokine induced by
gamma interferon (MIG), and IL-1RA—in all T-cell neoplasms (P < 0.05). In the angioimmunoblastic subset, all seven cyto-
kines except IP-10 and in the peripheral T-cell lymphoma (TCL)-not otherwise specified subset, only IP-10, sIL-2Rα, MIG,
and IL-8 were statistically elevated compared with control. Of these, elevated cytokines all but EGF were predictive of an
inferior EFS; IL-1RA, sIL-2Rα, and MIG predicted an inferior OS. In a multivariate analysis, sIL-2Rα [hazard ratio
(HR) = 3.95; 95% confidence interval (CI) 1.61–8.38] and IL-1RA (HR = 3.28; 95% CI 1.47–7.29) levels remained independ-
ent predictors of inferior EFS. TCL cell lines secreted high levels of sIL-2Rα and expressed the IL-2Rα surface receptor.
Conclusions: This report describes the cytokines relevant to prognosis in patients with untreated TCL and provides the
rationale to include serum IL-1RA and sIL-2Rα as biomarkers in future trials. Inhibition of these cytokines may also be of
therapeutic benefit.
Key words: T-cell lymphoma, cytokines, IL-1RA, sIL-2Rα, PTCL-NOS, AITL
introduction
T-cell lymphoma (TCL) comprises ∼10% of all non-Hodgkin
lymphoma (NHL) in the United States and up to 20% of cases
in Asia [1]. TCL are currently classified by WHO criteria [2, 3],
with the most common subtypes being peripheral TCL-not
otherwise specified (PTCL-NOS), angioimmunoblastic TCL
(AITL), anaplastic large cell (ALCL), and the predominant
subsets of cutaneous TCL (CTCL), Sézary syndrome (SS) and
mycosis fungoides (MF). The long-term outcome of the non-
CTCL groups remains poor with ∼30% of patients being cured
[4]. Induction therapy is typically with cyclophosphamide,
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